A. Members, A. Camm, G. Lip, R. Caterina, I. Savelieva et al., 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association, European Heart Journal, vol.4, issue.1, pp.2719-2766, 2012.
DOI : 10.1161/CIRCEP.110.955393

A. Go, E. Hylek, K. Phillips, Y. Chang, L. Henault et al., Prevalence of Diagnosed Atrial Fibrillation in Adults, JAMA, vol.285, issue.18, pp.2370-2375, 2001.
DOI : 10.1001/jama.285.18.2370

S. Stewart, C. Hart, D. Hole, and J. Mcmurray, Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study, Heart, vol.86, issue.5, 2001.
DOI : 10.1136/heart.86.5.516

R. Nieuwlaat, A. Capucci, A. Camm, S. Olsson, D. Andresen et al., Atrial fibrillation management: a prospective survey in ESC Member Countries, European Heart Journal, vol.26, issue.22, pp.2422-2456, 2005.
DOI : 10.1186/1471-2261-4-18

M. Nabauer, A. Gerth, T. Limbourg, S. Schneider, M. Oeff et al., The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol, 2009.

P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm et al., Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol, pp.1006-1029, 2007.

S. Stewart, C. Hart, D. Hole, and J. Mcmurray, A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study, The American Journal of Medicine, vol.113, issue.5, pp.359-64, 2002.
DOI : 10.1016/S0002-9343(02)01236-6

P. Kirchhof, A. Auricchio, J. Bax, H. Crijns, J. Camm et al., Outcome parameters for trials in atrial fibrillation: executive summary, Eur Heart J, 2007.

S. Knecht, C. Oelschläger, T. Duning, H. Lohmann, J. Albers et al., Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy, European Heart Journal, vol.110, issue.5646, pp.2125-2157, 2008.
DOI : 10.1126/science.1090349

G. Thrall, D. Lane, D. Carroll, and G. Lip, Quality of Life in Patients with Atrial Fibrillation: A Systematic Review, The American Journal of Medicine, vol.119, issue.5, pp.448-449, 2006.
DOI : 10.1016/j.amjmed.2005.10.057

M. Hughes and G. Lip, Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation

L. Friberg, M. Rosenqvist, and G. Lip, Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study, European Heart Journal, vol.4, issue.12, pp.1500-1510, 2012.
DOI : 10.1161/CIRCOUTCOMES.110.958108

A. Investigators, S. Connolly, J. Pogue, R. Hart, S. Hohnloser et al., Effect of clopidogrel added to aspirin in patients with atrial fibrillation, N Engl J Med, vol.360, issue.20, pp.2066-78, 2009.

L. Friberg, L. Benson, M. Rosenqvist, and G. Lip, Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study, BMJ, vol.344, issue.may30 3, p.3522, 2012.
DOI : 10.1136/bmj.e3522

J. Olesen, L. Fauchier, D. Lane, S. Taillandier, and G. Lip, Risk Factors for Stroke and Thromboembolism in Relation to Age Among Patients With Atrial Fibrillation, Chest, vol.141, issue.1, pp.147-53, 2012.
DOI : 10.1378/chest.11-0862

I. Ahrens, G. Lip, and K. Peter, New oral anticoagulant drugs in cardiovascular disease, Thrombosis and Haemostasis, vol.104, issue.1, pp.49-60, 2010.
DOI : 10.1160/TH09-05-0327

G. Lip, T. Larsen, F. Skjøth, and L. Rasmussen, Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation, Journal of the American College of Cardiology, vol.60, issue.8, pp.738-784, 2012.
DOI : 10.1016/j.jacc.2012.03.019

D. Caterina, R. Husted, S. Wallentin, L. Andreotti, F. Arnesen et al., New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes, Journal of the American College of Cardiology, vol.59, issue.16, pp.1413-1438, 2012.
DOI : 10.1016/j.jacc.2012.02.008

J. Douxfils, F. Mullier, S. Robert, C. Chatelain, B. Chatelain et al., Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate, Thromb Haemost, 2012.

M. Huisman, G. Lip, H. Diener, M. Brueckmann, J. Van-ryn et al., Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice, Thrombosis and Haemostasis, vol.107, issue.5, pp.838-885, 2012.
DOI : 10.1160/TH11-10-0718

V. Pengo, L. Crippa, A. Falanga, G. Finazzi, F. Marongiu et al., Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA) Thromb Haemost, pp.868-76, 2011.

E. Eerenberg, P. Kamphuisen, M. Sijpkens, J. Meijers, H. Buller et al., Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects, Circulation, vol.124, issue.14, pp.1573-1582, 2011.
DOI : 10.1161/CIRCULATIONAHA.111.029017

R. Marlu, E. Hodaj, A. Paris, P. Albaladejo, J. Cracowski et al., Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban, Thrombosis and Haemostasis, vol.108, issue.2, 2012.
DOI : 10.1160/TH12-03-0179

J. Van-ryn, J. Stangier, S. Haertter, K. Liesenfeld, W. Wienen et al., Dabigatran etexilate ??? a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity, Thrombosis and Haemostasis, vol.103, issue.6, pp.1116-1143, 2010.
DOI : 10.1160/TH09-11-0758

R. Nagarakanti, M. Ezekowitz, J. Oldgren, S. Yang, M. Chernick et al., Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion, Circulation, vol.123, issue.2, pp.131-137, 2011.
DOI : 10.1161/CIRCULATIONAHA.110.977546

J. Eikelboom, L. Wallentin, S. Connolly, M. Ezekowitz, J. Healey et al., Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of longterm anticoagulant therapy (RE-LY) trial. Circulation, pp.2363-72, 2011.

M. Matute, J. Masjuan, J. Egido, B. Fuentes, P. Simal et al., Safety and Outcomes following Thrombolytic Treatment in Stroke Patients Who Had Received Prior Treatment with Anticoagulants, Cerebrovascular Diseases, vol.363, issue.3, pp.231-240, 2012.
DOI : 10.1016/S0140-6736(04)15692-4

P. Alboni, G. Botto, and N. Baldi, Outpatient treatment of recurrent atrial fibrillation with the " pill-in-the-pocket " approach: practical aspects]. Ital Heart J Suppl Off J Ital Fed Cardiol, pp.335-375, 2005.

P. Alboni, G. Botto, N. Baldi, M. Luzi, V. Russo et al., Outpatient Treatment of Recent-Onset Atrial Fibrillation with the ???Pill-in-the-Pocket??? Approach, New England Journal of Medicine, vol.351, issue.23, pp.2384-91, 2004.
DOI : 10.1056/NEJMoa041233

P. Kirchhof, L. Eckardt, P. Loh, K. Weber, R. Fischer et al., Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial, The Lancet, vol.360, issue.9342, pp.1275-1284, 2002.
DOI : 10.1016/S0140-6736(02)11315-8

H. Oral, J. Souza, G. Michaud, B. Knight, R. Goyal et al., Facilitating Transthoracic Cardioversion of Atrial Fibrillation with Ibutilide Pretreatment, New England Journal of Medicine, vol.340, issue.24, pp.1849-54, 1999.
DOI : 10.1056/NEJM199906173402401

E. Manios, H. Mavrakis, E. Kanoupakis, E. Kallergis, D. Dermitzaki et al., Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study. Cardiovasc Drugs Ther Spons Int Soc Cardiovasc Pharmacother, pp.31-40, 2003.

L. Bianconi, M. Mennuni, V. Lukic, A. Castro, M. Chieffi et al., Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: A placebo-controlled study, Journal of the American College of Cardiology, vol.28, issue.3, pp.700-706, 1996.
DOI : 10.1016/0735-1097(96)00230-6

P. Taboulet, J. Duchenne, H. Lefort, C. Zanker, P. Jabre et al., Management of atrial fibrillation in emergency medicine. French society of emergency medicine (SFMU) guidelines with the contribution of the French society of cardiology (SFC), Annales fran??aises de m??decine d'urgence, vol.5, issue.4, pp.260-79, 2015.
DOI : 10.1007/s13341-015-0554-3